Safety, Efficacy, and Biomarker Results from an Open-Label, Multicenter, Phase I Study of RP2 Alone or Combined with Nivolumab in a Cohort of Patients

Safety, Efficacy, and Biomarker Results from an Open-Label, Multicenter, Phase I Study of RP2 Alone or Combined with Nivolumab in a Cohort of Patients

Uveal melanoma (UM) is a severe ocular malignant tumor that threatens patients' vision and survival. Despite some progress in treatment methods in recent years, the survival rate of patients has not significantly improved due to the lack of effective drugs, especially those that inhibit metastasis. At the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, several rapid oral reports focused on the challenges of UM treatment and presented the latest research findings. Oncology Frontier has compiled relevant studies for readers.
Professor Man Li:  From Uncertainty to Definitive Evidence—PostMONARCH Study Proves the Benefit of Cross-Line Treatment with CDK4/6 Inhibitors| Man Talks Breast Cancer: ASCO Special

Professor Man Li:  From Uncertainty to Definitive Evidence—PostMONARCH Study Proves the Benefit of Cross-Line Treatment with CDK4/6 Inhibitors| Man Talks Breast Cancer: ASCO Special

In this "Man Talks Breast Cancer: ASCO Special," Professor Man Li's team from The Second Affiliated Hospital of Dalian Medical University has selected the latest ASCO studies on HR+ advanced breast cancer, covering topics such as cross-line treatment with CDK4/6 inhibitors, novel ADCs combined with ICIs, and comparing CDK4/6 inhibitors + ET with chemotherapy in premenopausal women. These can provide more valuable insights for clinical practice.
ASCO China Voice | Professor Min Yan: Utidelone Combined with Bevacizumab is Safe and Effective for Treating Brain Metastases in HER2-Negative Breast

ASCO China Voice | Professor Min Yan: Utidelone Combined with Bevacizumab is Safe and Effective for Treating Brain Metastases in HER2-Negative Breast

Brain metastasis from breast cancer has a high incidence, second only to lung cancer . Previous studies have shown that patients with brain metastases have poorer survival compared to those without brain metastases, with HER2-negative breast cancer brain metastasis patients having an even worse prognosis . Due to the blood-brain barrier (BBB), many drug treatments have limited intracranial objective response rates (ORR). Utidelone, a novel microtubule inhibitor developed in China, has shown potential for treating brain metastases due to its unique physicochemical properties that allow it to penetrate the BBB. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, a multicenter phase II study led by Professor Min Yan from Henan Cancer Hospital was selected for presentation. This study explored the efficacy and safety of utidelone combined with bevacizumab in treating HER2-negative breast cancer brain metastases. "Oncology Frontier" invited Professor Min Yan to discuss the progress in treating breast cancer brain metastases, the study design and findings, and future perspectives.
Venetoclax±BTKi-Based Chemotherapy as a Potential Bridging Therapy Before CAR-T Treatment for Relapsed/Refractory B-Cell Lymphoma

Venetoclax±BTKi-Based Chemotherapy as a Potential Bridging Therapy Before CAR-T Treatment for Relapsed/Refractory B-Cell Lymphoma

The efficacy of CAR-T therapy in B-cell lymphoma is increasingly recognized, and its real-world application is expanding. However, patients with high tumor burden face a high incidence of cytokine release syndrome (CRS) and poor outcomes, leading to high treatment-related mortality. There is an urgent need for effective bridging therapies to reduce CRS incidence and improve remission rates in relapsed/refractory B-cell lymphoma patients. From June 13-16, 2024, the 29th European Hematology Association (EHA) Annual Meeting will take place. Dr.  Rui Liu, head of the research team of Professors Xiaoyan Ke and Kai Hu from Beijing Gaobo Hospital, will present a poster titled “VENETOCLAX AND BTK INHIBITORS BASED CHEMOTHERAPY IS A POTENTIAL EFFECTIVE CAR-T BRIDGING THERAPY IN R/R B-NHL,” offering new insights into bridging therapies before CAR-T for relapsed/refractory B-cell lymphoma.